Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in india

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Raizada, Neeraj ^a   Sachdeva, K S ^b   Sreenivas, Achuthan ^c   Vadera, Bhavin ^a   Gupta, R S ^b   Parmar, Malik ^c   Kulsange, Shubhangi ^a   Babre, Ameet ^a   Thakur, Rahul ^a   Gray, Christen ^d   Ramachandran, Ranjani ^c   Alavadi, Umesh ^a   Ghedia, Mayank ^c   Vollepore, Balasangameshwara ^a   Dewan, Puneet ^c   Boehme, Catharina ^d   Paramsivan, C N ^a  

^a Foundation for Innovative New Diagnostics   (India)

^b Central TB Division   (India)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPUTER PROGRAM; COMPUTER SYSTEM; DECENTRALIZATION; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; FEASIBILITY STUDY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; INDIA; MAJOR CLINICAL STUDY; POWER SUPPLY; RIF TEST; RISK FACTOR; TEMPERATURE; TUBERCULOSIS; VALIDITY; XPERT MTB TEST; DRUG EFFECTS; GENETICS; HEALTH CARE DELIVERY; MYCOBACTERIUM TUBERCULOSIS; ORGANIZATION AND MANAGEMENT; TUBERCULOSIS, MULTIDRUG-RESISTANT;

NUCLEIC ACID; RIFAMPICIN;

DELIVERY OF HEALTH CARE; FEASIBILITY STUDIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INDIA; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACIDS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84896285403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089301     Document Type: Article

References (21)

1. World Health Organization The Stop TB Department (2010) Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB.
2. World Health Organization (2010) Frequently Asked Questions on Xpert MTB/RIF assay: 1-5.
3. Evans CA (2011) GeneXpert - A Game-Changer for Tuberculosis Control? PLoS Med 8: 8-11. doi:10.1371/journal.pmed.1001061. Available: http://www.ncbi.nlm. nih.gov/pmc/articles/PMC3144196/Accessed on 24 May 2013
4. World Health Organization (2011) Rapid Implementation of the Xpert MTB/RIF diagnostic test Technical and Operational 'How - to'; Practical consideration. Available: http://whqlibdoc.who.int/publications/2011/ 9789241501569-eng.pdf.
5. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. N Engl J Med 363: 1005-1015. Available: http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907847.
6. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and eff ectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495-1505. doi:10.1016/S0140- 6736(11)60438-8.
7. Cepheid (2009) Xpert MTB/RIF Two-hour detection of MTB and resistance to rifampicin.
8. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M DN (2013) Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review). Chochrane Database Syst Rev. Available: http://onlinelibrary. wiley.com/doi/10.1002/14651858.CD009593.pub2/pdf.
9. National Health Laboratory Service South Africa (2013) GeneXpert MTB/RIF Progress Report February 2013.
10. Tukvadze N, Kempker RR, Kalandadze I, Kurbatova E, Leonard MK, et al. (2012) Use of a Molecular Diagnostic Test in AFB Smear Positive Tuberculosis Suspects Greatly Reduces Time to Detection of Multidrug Resistant Tuberculosis. PLoS One 7: e31563. doi:10.1371/journal.pone.0031563.
11. Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, et al. (2010) Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis 10: 41. doi:10.1186/1471-2334-10-41.
12. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME (2008) Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 177: 787-792. doi:10.1164/rccm.200709-1436OC. (Pubitemid 351490566)
13. World Health Organisation-Expert Group Report (2008) Molecular Line Probe Assays For Rapid Screening Of Patients At Risk Of Multi-Drug Resistant Tuberculosis (MDR-TB)
14. Nikolayevsky V, et al. (2009) Performance of the Genotype® MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol 9: 1-9. doi:10.1186/1472-6890-9-2.
15. World Health Organization (2007) Use of Liquid TB Culture and Drug Susceptibility Testing (DST) in Low and Medium Income Settings Summary report of the Expert Group Meeting on the use of liquid culture media.
16. Central TB Division Ministry of Health and Family Welfare (2009) Training Manual for Mycobacterium tuberculosis Culture & Drug susceptibility testing. New Delhi, India
17. World Health Organization (2011) Automated Real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. Geneva, Switzerland.
18. World Health Organization- The STOP TB Department (2012) Update - Implementation and roll-out of Xpert MTB/RIF May 2012. Available: http://www.stoptb.org/wg/gli/assets/documents/Xpert%20MTB- RIF%20UPDATE%20May%202012.pdf
19. Chemhuru M, Duka M, Bernardin Nanan-n'zeth KJ, Simons S, Van Den Broucke S, et al. (2013) Implementation of Xpert MTB/RIF Assay in Buhera District, Zimbabwe: Lessons learned Available: http://www.msf.org.za/sites/default/files/ publication/documents/GeneXpert-report-Lessons-learned-with-paralel-testing.pdf. Accessed 24 May 2013
20. Cepheid (2013) Improving your experience with Xpert MTB/RIF," Cepheid HDBC, 2012. Available: http://www.ghdonline.org/uploads/Improving-your- experience-of-Xpert-MTB-RIF.pdf. Accessed 24 May 2013
21. André E, Chirambiza JP, Nyota R, Kalumuna D, Creswell J, et al. (2013) Lessons learned from early implementation of GeneXpert MTB/RIF technology in a remote area of the Democratic Republic of Congo in 19th Conference of the Union Africa Region Kigali